Approval · Notice of Compliance 14375 · 2013
ALIMTA: Notice of Compliance 14375
Issued May 9, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14375
- Date
- May 9, 2013
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Extension of Maintenance Therapy- Nonsquamous Non-Small Cell Lung Cancer (NSCLC) - monotherapy indication to permit continuous Alimta maintenance treatment in patients with advanced nonsquamous NSCCLC, immediately following Alimta-containing first-line platinum doublet chemotherapy
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALIMTA | Not yet assigned | — |
Medicinal ingredients
- PEMETREXED DISODIUM 100 MG per VIAL
- PEMETREXED DISODIUM 500 MG per VIAL